ReviewCurrent hematologic malignancy reports2015
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
Review in Current hematologic malignancy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.Life (Basel, Switzerland) · 2024Review
- Cutaneous T-Cell Lymphoma and Microbiota: Etiopathogenesis and Potential New Therapeutic Targets.Dermatology research and practice · 2024Review
- Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.ACS medicinal chemistry letters · 2022Article
- Article
- Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.Journal of hematology & oncology · 2019Article
- A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL).Oncotarget · 2018Article
- Early morphea simulating patch-stage mycosis fungoides in two cases.Dermatology reports · 2018Article
- Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.Current oncology reports · 2018Review
- Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.Cancer chemotherapy and pharmacology · 2018Article
- Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.Current hematologic malignancy reports · 2017Review
- Article
- Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Oncotarget · 2016Review
- An overview of cutaneous T cell lymphomas.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of MF and SS have broadened the therapeutic targets; here, we review emerging concepts in the pathogenesis of MF and SS as well as novel and traditional systemic therapies for MF and SS. These include histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, and belinostat), monoclonal antibodies (alemtuzumab, brentuximab vedotin, and mogamulizumab) and single-agent cytotoxic chemotherapeutic agents (e.g., pralatrexate, doxorubicin, bendamustine, and forodesine), as well as multi-agent chemotherapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.